Core Viewpoint - Jinling Pharmaceutical announced that its subsidiary Chizhou Dongsheng Pharmaceutical has received approval from the National Medical Products Administration for the registration of potassium sulfate, which is a raw material for oral solutions used for bowel cleansing before medical procedures. This approval indicates that the raw material meets domestic drug registration requirements and can be produced and sold in the domestic market, enhancing the company's product line in raw materials. However, production and sales will take time, and it will not have a significant impact on the company's current performance [1]. Summary by Relevant Categories - **Regulatory Approval**: The approval for potassium sulfate registration has been granted by the National Medical Products Administration, allowing for its production and sale in the domestic market [1]. - **Product Line Expansion**: This approval will enrich the company's raw material product line, providing more options for its offerings [1]. - **Impact on Performance**: The company indicates that the production and sales of potassium sulfate will take time, and therefore, it will not significantly affect the company's current financial performance [1].

Group 1 - The stock price of Jinling Pharmaceutical reached 7.28 yuan as of the close on August 22, 2025, with an increase of 0.02 yuan, representing a rise of 0.28% compared to the previous trading day [1] - The trading volume on that day was 171,300 hands, with a total transaction amount of 125 million yuan [1] - Jinling Pharmaceutical is primarily engaged in the research, development, production, and sales of traditional Chinese medicine, chemical raw materials, and formulations, covering multiple therapeutic areas including cardiovascular, anti-tumor, and digestive systems [1] Group 2 - As of August 20, 2025, the total number of shareholders for Jinling Pharmaceutical was 37,622 [1] - On August 22, the net inflow of main funds was 6.3088 million yuan, with a cumulative net inflow of 18.0238 million yuan over the past five days [1]

证券日报网讯金陵药业（000919）8月22日在互动平台回答投资者提问时表示，截至2025年8月20日公司 股东人数为37622户。 ...

Group 1 - The high-pressure oxygen chamber concept sector experienced a decline of 0.76%, ranking among the top declines in concept sectors as of the market close on August 22 [1] - Within the sector, major declines were observed in companies such as Samsung Medical, Aoyang Health, and Dahu Co., with notable increases in Hangyang Co., Yinkang Life, and International Medicine, which rose by 0.97%, 0.86%, and 0.37% respectively [1] Group 2 - The high-pressure oxygen chamber concept sector saw a net outflow of 260 million yuan in principal funds today, with six stocks experiencing net outflows [2] - The stock with the highest net outflow was Tiedao Heavy Industry, which had a net outflow of 143 million yuan, followed by Innovative Medical, Samsung Medical, and Aoyang Health with net outflows of 60.83 million yuan, 43.65 million yuan, and 13.12 million yuan respectively [2] - Conversely, the stocks with the highest net inflows included International Medicine, Jinling Pharmaceutical, and Yinkang Life, with net inflows of 3.35 million yuan, 3.27 million yuan, and 3.20 million yuan respectively [2]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：000919 证券简称：金陵药业 公告编号：2025-057 金陵药业股份有限公司关于分公司收到 药品再注册批准通知书的公告 一、申请注册药品的基本情况 受理号：CYHZ2514512闽 药品名称：水解蛋白注射液 申请事项：境内生产药品再注册 许可药品注册分类：化学药品 规格：500ml:25g(水解蛋白) 上市许可持有人：金陵药业股份有限公司福州梅峰制药厂 审批结论：经审查，同意本品再注册。由于本品长期未生产，恢复生产时，须向省级药品监督管理部门 提出现场检查申请，经现场检查合格且抽取三批产品检验合格后，方可上市销售。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 金陵药业股份有限公司（以下简称"公司"）分公司金陵药业股份有限公司福州梅峰制药厂于近日收到福 建省药品监督管理局下发的药品再注册批准通知书（2025R079210），现将相关情况公告如下： 水解蛋白注射液为水解物酪蛋白和乳蛋白与山梨醇的灭菌溶液，主要用于手术严重创伤、大面积烧伤引 起的严重氨基酸缺乏，以及各种疾病引起的低蛋白血症。 三、 ...

Policy Developments - The National Healthcare Security Administration issued the "Guidelines for the Establishment of Pricing Projects for Physical Therapy Medical Services (Trial)" which integrates existing pricing projects into 32 items, with 7 additional charges and 1 expansion item [2] Medical Device Approvals - In July, the National Medical Products Administration approved 295 medical device products, including 240 domestic Class III devices, 21 imported Class III devices, 29 imported Class II devices, and 5 devices from Hong Kong, Macau, and Taiwan [4] Company Announcements - New Industries announced that 18 of its chemiluminescent reagent products received IVDR CE certification, allowing them to enter the EU market, which is expected to enhance the company's competitiveness [5] - Jining Pharmaceutical received a drug re-registration approval for hydrolyzed protein injection, which is used for severe amino acid deficiency and will help restore normal production and sales [6] - Chongqing Pharmaceutical Holdings reported a net profit of 282 million yuan for the first half of the year, with a revenue of 41.188 billion yuan, marking a 3.54% year-on-year increase [8] - Jimin Health reported a net loss of 52.6959 million yuan for the first half of 2025, with a revenue of 36.6 million yuan, down 21.30% year-on-year [9] - Chenguang Bio announced plans to transfer 97.5% of its subsidiary Chenguang Tianrun Pharmaceutical to Sichuan Tongsheng Biomedical, with the transfer based on the subsidiary's equity as of July 31, 2025 [11] - Baiyang Pharmaceutical's controlling shareholder plans to increase capital and change the shareholding structure, with a new entity set to acquire 80% of the controlling group [13] Industry Events - A groundbreaking cervical spine surgery was successfully performed in Shanghai, utilizing innovative "satellite steel plate" technology to stabilize a severely injured patient's spine [15] - Guangxi plans to provide free HPV vaccinations to nearly 960,000 eligible girls from 2025 to 2027, emphasizing the importance of preventive healthcare [16] Shareholder Actions - Multiple shareholders of Sanxin Medical plan to reduce their stakes in the company due to personal financial needs, with specific share amounts outlined for each individual [18]

证券日报网讯8月20日晚间，金陵药业（000919）发布公告称，公司分公司金陵药业股份有限公司福州 梅峰制药厂于近日收到福建省药品监督管理局下发的药品再注册批准通知书。 ...

格隆汇8月20日丨金陵药业(000919.SZ)公布，公司分公司金陵药业股份有限公司福州梅峰制药厂于近日 收到福建省药品监督管理局下发的水解蛋白注射液的药品再注册批准通知书(2025R079210)。水解蛋白 注射液为水解物酪蛋白和乳蛋白与山梨醇的灭菌溶液，主要用于手术严重创伤、大面积烧伤引起的严重 氨基酸缺乏，以及各种疾病引起的低蛋白血症。 ...

格隆汇8月20日丨金陵药业(000919.SZ)公布，公司分公司金陵药业股份有限公司福州梅峰制药厂于近日 收到福建省药品监督管理局下发的水解蛋白注射液的药品再注册批准通知书(2025R079210)。水解蛋白 注射液为水解物酪蛋白和乳蛋白与山梨醇的灭菌溶液，主要用于手术严重创伤、大面积烧伤引起的严重 氨基酸缺乏，以及各种疾病引起的低蛋白血症。 ...

Group 1 - The high-pressure oxygen chamber concept declined by 0.68%, ranking among the top declines in concept sectors as of the market close on August 20 [1] - Within the high-pressure oxygen chamber sector, companies such as Innovate Medical, Yinkang Life, and Aoyang Health experienced significant declines, while Iron Construction Heavy Industry, Samsung Medical, and Dahu Co. saw increases of 4.29%, 1.08%, and 0.89% respectively [1] - The high-pressure oxygen chamber sector experienced a net outflow of 444 million yuan in main funds, with Innovate Medical leading the outflow at 537 million yuan [2] Group 2 - The top gainers in the market included the Tonghuashun Fruit Index at 3.70%, AI mobile phones at 2.77%, and MCU chips at 2.60%, while the high-pressure oxygen chamber concept was among the top decliners [2] - The main funds saw significant outflows from several stocks in the high-pressure oxygen chamber sector, with Innovate Medical, Aoyang Health, and Dahu Co. being the most affected [2] - Conversely, Iron Construction Heavy Industry, Samsung Medical, and Jinling Pharmaceutical attracted net inflows of main funds, indicating a shift in investor interest [2]